Maxcyte (MXCT) Cost of Revenue (2020 - 2025)
Historic Cost of Revenue for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to $3.9 million.
- Maxcyte's Cost of Revenue fell 3658.77% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.9 million, marking a year-over-year decrease of 2005.77%. This contributed to the annual value of $26.7 million for FY2024, which is 116.4% down from last year.
- Per Maxcyte's latest filing, its Cost of Revenue stood at $3.9 million for Q3 2025, which was down 3658.77% from $5.8 million recorded in Q2 2025.
- In the past 5 years, Maxcyte's Cost of Revenue registered a high of $7.4 million during Q1 2024, and its lowest value of $2.8 million during Q1 2021.
- Moreover, its 5-year median value for Cost of Revenue was $5.7 million (2025), whereas its average is $5.3 million.
- In the last 5 years, Maxcyte's Cost of Revenue skyrocketed by 7069.75% in 2021 and then tumbled by 3658.77% in 2025.
- Over the past 5 years, Maxcyte's Cost of Revenue (Quarter) stood at $4.1 million in 2021, then surged by 31.49% to $5.4 million in 2022, then soared by 33.85% to $7.2 million in 2023, then fell by 10.06% to $6.5 million in 2024, then tumbled by 39.19% to $3.9 million in 2025.
- Its Cost of Revenue stands at $3.9 million for Q3 2025, versus $5.8 million for Q2 2025 and $5.7 million for Q1 2025.